A study, published in the Journal of the National Cancer Institute, identified genes that predispose the African American population to breast cancer.1
Importantly, the study also...
Elizabeth Plimack, MD, MS, of the Fox Chase Cancer Center in Philadelphia, discussed the role of subsequent immunotherapy when analyzing the primary endpoint of...
Meletios A. Dimopoulos, MD, discussed the phase III Boston study presented at the 2020 ASCO Virtual Scientific Program examining a new combination therapy to...
Results from the randomized phase III ASPEN trial, presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Meeting, indicated that zanubrutinib...
Clinical outcomes improved and reduced markers of inflammation were seen after administration of acalabrutinib (Calquence) for patients with severe coronavirus disease 2019 (COVID-19), according...
The combination use of belantamab mafodotin plus bortezomib (Velcade) and dexamethasone (B-Vd) induced high clinical benefit rates and a tolerable safety profile in patients...
Results from the interim analysis of the phase II ZUMA-5 study, presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program,...
JNJ-4528, a chimeric antigen receptor (CAR) T-cell therapy, continued to demonstrate deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma, according...
The combination use of niraparib (Zejula) plus bevacizumab (Avastin) significantly improved clinical outcomes, compared with niraparib alone, in patients with recurrent ovarian cancer, according...
In an interview with CancerNetwork®, Nirav Niranjan Shah, MD, of the Medical College of Wisconsin, discussed the use of autologous stem cell transplant in...
Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeting CAR T-cell therapy, yielded a response in73% of patients with heavily pretreated relapsed/refractory multiple myeloma, according to topline...
